Selvita S.A. Logo

Selvita S.A.

ISIN: PLSLVCR00029 | Ticker: SLV | LEI: 25940057WQ9YP5MOQF28
Sector: Health CareSub-Industry: Pharmaceuticals
Country: Poland

About Selvita S.A.

Company Description

We are one of the largest preclinical contract research organizations in Europe, driven by a clear mission:

to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development.

We have grown from a 20-people start-up to a global organization, yet we still focus on the same goal:
to become a true partner for our Clients, providing multidisciplinary support in their toughest research challenges.

We provide high-quality drug discovery and drug development services. We have the necessary expertise and know-how to support drug discovery projects across a broad range of therapeutic areas. We offer a range of stand-alone or fully integrated drug discovery and development solutions spanning the entire value chain from early drug discovery to preclinical development.

Year founded

2007

Served area

Worldwide

Headquarters

Bobrzyńskiego 14, 30-348 Kraków – Poland

Financial statements

Download as Excel
Line item in (pln) 22.03.2019 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A 90,886,840.00 218,795,827.00 455,923,000.00 584,911,000.00
Noncurrent Assets N/A 44,942,779.00 75,826,002.00 276,798,000.00 381,829,000.00
Property Plant And Equipment N/A 10,282,357.00 23,317,372.00 62,106,000.00 160,908,000.00
Goodwill N/A 280,740.00 280,740.00 76,732,000.00 78,057,000.00
Intangible Assets Other Than Goodwill N/A 588,229.00 627,640.00 37,178,000.00 34,791,000.00
Deferred Tax Assets N/A 8,520,949.00 12,339,284.00 11,776,000.00 10,094,000.00
Other Noncurrent Assets N/A 343,335.00 345,235.00 829,000.00 1,060,000.00
Current Assets N/A 45,944,061.00 142,969,825.00 179,125,000.00 203,082,000.00
Inventories N/A 1,184,882.00 2,230,344.00 1,942,000.00 7,801,000.00
Trade And Other Current Receivables N/A 25,854,362.00 33,997,866.00 65,616,000.00 98,802,000.00
Other Current Financial Assets N/A 0.00 10,152,560.00 13,435,000.00 2,018,000.00
Other Current Nonfinancial Assets N/A 1,010,222.00 1,069,264.00 4,263,000.00 5,100,000.00
Cash and cash equivalents 0.00 13,667,930.00 93,005,000.00 83,550,000.00 74,157,000.00
Equity And Liabilities N/A 90,886,840.00 218,795,827.00 455,923,000.00 584,911,000.00
Equity 0.00 44,668,792.00 152,660,000.00 205,554,000.00 273,161,000.00
Issued Capital N/A 12,876,983.00 14,684,379.00 14,684,000.00 14,684,000.00
Retained Earnings N/A 0.00 5,523,002.00 N/A N/A
Retained Earnings Profit Loss For Reporting Period N/A N/A N/A 14,899,000.00 30,309,000.00
Retained Earnings Excluding Profit Loss For Reporting Period N/A N/A N/A 23,521,000.00 38,513,000.00
Share Premium N/A 2,888,750.00 86,448,193.00 86,448,000.00 86,448,000.00
Treasury Shares N/A N/A N/A 0.00 0.00
Other Reserves N/A -2,988,750.00 0.00 N/A N/A
Capital Reserve N/A 22,993,414.00 22,993,414.00 22,994,000.00 22,994,000.00
Equity Attributable To Owners Of Parent N/A 41,231,445.00 147,298,404.00 196,870,000.00 262,178,000.00
Noncontrolling Interests N/A 3,437,347.00 5,361,188.00 8,684,000.00 10,983,000.00
Liabilities N/A 46,218,048.00 66,136,235.00 250,369,000.00 311,750,000.00
Noncurrent Liabilities N/A 21,588,545.00 33,288,032.00 154,513,000.00 189,083,000.00
Noncurrent Deferred Income Including Noncurrent Contract Liabilities N/A N/A N/A 2,043,000.00 11,020,000.00
Deferred Tax Liabilities N/A 2,939,627.00 4,470,563.00 6,943,000.00 6,323,000.00
Noncurrent Recognised Liabilities Defined Benefit Plan N/A 103,028.00 259,824.00 530,000.00 239,000.00
Longterm Borrowings N/A N/A N/A 80,966,000.00 109,088,000.00
Current Liabilities N/A 24,629,503.00 32,848,203.00 95,856,000.00 122,667,000.00
Current Provisions N/A 0.00 0.00 N/A N/A
Trade And Other Current Payables N/A 11,001,479.00 10,428,959.00 31,331,000.00 49,185,000.00
Current Contract Liabilities N/A 557,787.00 363,196.00 3,621,000.00 3,351,000.00
Current Deferred Income Other Than Current Contract Liabilities N/A N/A N/A 855,000.00 2,120,000.00
Accruals Classified As Current N/A 5,713,501.00 7,908,264.00 22,485,000.00 24,054,000.00
Current Tax Liabilities Current N/A 229,198.00 416,458.00 2,762,000.00 2,493,000.00
Line item in (pln) 22.03.2019/
01.01.2020
01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 30,443,469.00 137,356,285.00 310,921,000.00 407,462,000.00
Raw Materials And Consumables Used 4,665,041.00 21,001,384.00 59,665,000.00 68,394,000.00
Services Expense 3,493,360.00 19,993,830.00 44,184,000.00 66,684,000.00
Employee Benefits Expense 14,344,783.00 65,198,967.00 121,527,000.00 155,991,000.00
Expense From Sharebased Payment Transactions With Employees N/A N/A 31,469,000.00 30,838,000.00
Depreciation And Amortisation Expense 2,629,819.00 13,525,722.00 27,488,000.00 36,828,000.00
Tax Expense Other Than Income Tax Expense 234,290.00 1,174,920.00 1,757,000.00 2,043,000.00
Other Expense By Nature 1,197,244.00 1,938,919.00 3,975,000.00 9,426,000.00
Profit Loss From Operating Activities 5,374,587.00 19,544,158.00 26,085,000.00 44,775,000.00
Finance Income 20,978.00 12,830.00 14,000.00 4,000.00
Finance Costs 501,341.00 703,132.00 5,031,000.00 4,572,000.00
Profit Loss Before Tax 4,894,224.00 18,853,856.00 21,068,000.00 40,207,000.00
Income Tax Expense Continuing Operations -909,976.00 -1,068,063.00 2,846,000.00 7,599,000.00
Profit Loss From Continuing Operations 5,804,200.00 19,921,919.00 N/A N/A
Profit (loss) 5,804,200.00 19,921,919.00 18,222,000.00 32,608,000.00
Profit Loss Attributable To Owners Of Parent 5,523,002.00 17,998,078.00 14,899,000.00 30,309,000.00
Profit Loss Attributable To Noncontrolling Interests 281,198.00 1,923,841.00 3,323,000.00 2,299,000.00
Line item in (pln) 22.03.2019 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A 5,804,200.00 19,921,919.00 18,222,000.00 32,608,000.00
Adjustments For Decrease Increase In Inventories N/A 66,622.00 -1,045,462.00 289,000.00 -5,859,000.00
Adjustments For Provisions N/A 40,669.00 1,687,732.00 13,028,000.00 -911,000.00
Adjustments For Unrealised Foreign Exchange Losses Gains N/A -59,772.00 -46,819.00 142,000.00 4,068,000.00
Adjustments For Fair Value Gains Losses N/A N/A N/A 31,469,000.00 30,838,000.00
Cash Flows From Used In Operating Activities N/A 4,338,804.00 29,356,203.00 85,406,000.00 75,430,000.00
Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities N/A N/A N/A 133,535,000.00 0.00
Proceeds From Government Grants Classified As Investing Activities N/A N/A N/A 0.00 10,376,000.00
Cash Advances And Loans Made To Other Parties Classified As Investing Activities N/A 0.00 0.00 N/A N/A
Cash Receipts From Repayment Of Advances And Loans Made To Other Parties Classified As Investing Activities N/A 29,371.00 0.00 N/A N/A
Interest Received Classified As Investing Activities N/A 21,106.00 12,830.00 14,000.00 4,000.00
Cash Flows From Used In Investing Activities N/A 7,956,735.00 -25,143,366.00 -162,263,000.00 -79,789,000.00
Proceeds From Issuing Shares N/A 0.00 90,601,310.00 N/A N/A
Proceeds From Borrowings Classified As Financing Activities N/A 6,989.00 4,641.00 101,801,000.00 37,844,000.00
Repayments Of Borrowings Classified As Financing Activities N/A 34,464.00 6,989.00 9,173,000.00 11,296,000.00
Payments Of Lease Liabilities Classified As Financing Activities N/A 1,528,138.00 9,613,784.00 22,245,000.00 28,024,000.00
Interest Paid Classified As Financing Activities N/A 60,746.00 626,146.00 3,801,000.00 4,196,000.00
Cash Flows From Used In Financing Activities N/A 1,372,391.00 75,124,561.00 66,819,000.00 -5,672,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes N/A 13,667,930.00 79,337,398.00 -10,038,000.00 -10,031,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents N/A 0.00 0.00 583,000.00 638,000.00
Cash and cash equivalents 0.00 13,667,930.00 93,005,000.00 83,550,000.00 74,157,000.00

Please note that some sums might not add up.

Filings & Publications

Insider Trades

Sign up and we will give you access!

Capital markets information

ISIN

PLSLVCR00029

LEI

25940057WQ9YP5MOQF28

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Sub-Industry

Pharmaceuticals

Listed Stock Exchange

Warsaw Stock Exchange

Main Stock Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.